Sulfateq B.V. is dedicated to developing new drugs for several diseases: Acute Kidney Injury (AKI), Chronic Obstructive Pulmonary Disease (COPD), Type II Diabetes (T2D) and obesity. We can now proudly announce that the SUL-compounds are being tested in sepsis, which is a disease that is characterized by a life-threatening response of the host to an infection. The different immunological, neurological and physiological responses that occur result in organ failure. Current treatment of sepsis is limited to the symptomatic treatment by either antibiotics and or fluid drainage, so there is a need for an effective treatment.
The application of SUL-compounds in sepsis is being investigated by Dr. Hjalmar Bouma from the University Medical Centre Groningen (UMCG). Dr. Hjalmar Bouma is part of a special Sepsis research group that is currently investigating the effect of SUL-compounds in a mouse model for sepsis. He has been interviewed about sepsis and his study of the SUL-compounds. You can listen to this interview through this link (in Dutch). In addition, a sneak preview of this interview is already published. Note: both the interview and article are in Dutch.